Diosmin plus cabergoline for prevention of Ovarian Hyperstimulation Syndrome in high-risk women undergoing intracytoplasmic sperm injection (ICSI)
khalid abd aziz mohamed
250 participants
Feb 15, 2014
Interventional
Conditions
Summary
Objectives: To assess the effecacy of oral Diosmin in the prevention of ovarian hyperstimulation syndrome (OHSS) in high-risk women underwent intracytoplasmic sperm injection (ICSI). Study design: Prospective randomized controlled clinical trial. Patients and Methods: two hundred women at risk of ovarian hyperstimulation syndrome during ICSI cycles will be randomly scheduled into two equal groups. In group A, (Diosmin group), 2 tab every 8 hs Diosmin ( 500mg) plus 1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection .; while in group B (control group), 1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for eight days. The main outcome measures were rates and grades of OHSS, and the pregnancy rate in both groups.
Eligibility
Inclusion Criteria4
- infertile women with or without polcystic ovarian syndrome and candidate forICSI with one of the following:
- Presence of more than 20 follicles by ultrasound
- E2 more than 3000 pg/ml
- Retrieval of more than 15 follicles
Exclusion Criteria1
- none
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
n group A, (Diosmin group), 2 tablets every 8 hours Diosmin ( 500mg) will be given from the day of ovum retrieval and for 14 days plus 1 tab/day Cabergoline ( 0.5 mg) will be given at day of HCG injection and for eight days. all patient returned her empty medications boxes to ensure they are taking medications
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12614000535673